Open Payments

THE STAMFORD HOSPITAL

Type
Teaching hospital
Where
Stamford, CT
Medicare CCN
070006
Received
$711,278 in 79 records, 2025 ($27,781 general, $683,497 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment34$27,781
2025Research payment45$683,497

By company

CompanyRecordsAmountYears
PFIZER INC.15$240,7322025
Merck Sharp & Dohme LLC2$238,6742025
E.R. Squibb & Sons, L.L.C.3$135,2942025
Sumitomo Pharma America, Inc.11$26,0972025
Novartis Pharmaceuticals Corporation3$17,4692025
Genentech, Inc.7$16,1042025
Insulet Corporation21$13,6252025
Incyte Corporation2$5,0602025
Baxter Healthcare1$3,1792025
BIOTRONIK INC.1$3,0002025
AstraZeneca Pharmaceuticals LP1$3,0002025
Eli Lilly and Company1$2,5652025
Fisher Scientific Company L.L.C.2$2,0342025
Celgene Corporation1$1,5002025
Tandem Diabetes Care, Inc.4$1,4002025
Bioventus LLC2$1,2832025
Olympus America Inc.2$2582025

By nature of payment

NatureRecordsAmount
Research payment45$683,497
Compensation for services other than consulting, including serving as faculty or as a speaker at a v25$15,025
Debt forgiveness8$9,756
Space rental or facility fees (teaching hospital only)1$3,000

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$135,469Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm2025
2025-12-31Merck Sharp & Dohme LLC$103,204Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable 2025
2025-12-31PFIZER INC.$1,845Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-12-31Fisher Scientific Company L.L.C.$740Debt forgivenessCash or cash equivalent2025
2025-12-24PFIZER INC.$1,845Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-12-17PFIZER INC.$18,459Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-12-16PFIZER INC.$21,536Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-11-30BIOTRONIK INC.$3,000Debt forgivenessCash or cash equivalent2025
2025-11-27PFIZER INC.$13,697Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-11-19Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-11-10Novartis Pharmaceuticals Corporation$1,131Research paymentIn-kind items and servicesA Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-11-05Sumitomo Pharma America, Inc.$1,021Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-10-29Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-10-23Genentech, Inc.$985Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-10-22Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-09-24Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-09-10Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-09-03PFIZER INC.$58,317Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-08-29Olympus America Inc.$238Debt forgivenessIn-kind items and servicesSingle Use Aspiration Needle NA-U401SX Device, Endotherapy2025
2025-08-27Insulet Corporation$1,475Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-08-20PFIZER INC.$541Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-08-19Bioventus LLC$641Debt forgivenessIn-kind items and services2025
2025-08-19Bioventus LLC$641Debt forgivenessIn-kind items and services2025
2025-08-04Incyte Corporation$2,530Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2025
2025-07-30Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-07-28Eli Lilly and Company$2,565Research paymentCash or cash equivalentA PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS V2025
2025-07-24Incyte Corporation$2,530Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2025
2025-07-24Genentech, Inc.$1,635Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-07-23PFIZER INC.$436Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-07-22Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-07-15Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-07-08Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-07-03E.R. Squibb & Sons, L.L.C.$8,250Research paymentCash or cash equivalentConnect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist2025
2025-07-01Insulet Corporation$925Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-06-30Olympus America Inc.$20Debt forgivenessIn-kind items and services2025
2025-06-21PFIZER INC.$1,489Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-06-18Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-06-06PFIZER INC.$43,383Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-06-03Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-27Genentech, Inc.$9,753Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-05-27Genentech, Inc.$985Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-05-27Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-21Celgene Corporation$1,500Research paymentCash or cash equivalentConnect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist2025
2025-05-14Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-05-13Insulet Corporation$925Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-07Sumitomo Pharma America, Inc.$5,545Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-05-07Sumitomo Pharma America, Inc.$30Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-04-29PFIZER INC.$32,029Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-04-15Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-04-10PFIZER INC.$23,670Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-04-09Sumitomo Pharma America, Inc.$9,482Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-04-09Sumitomo Pharma America, Inc.$3,886Research paymentCash or cash equivalentORGOVYX Drug, PROSTATE CANCERA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2025
2025-04-08Novartis Pharmaceuticals Corporation$8,288Research paymentCash or cash equivalentA Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an2025
2025-04-03E.R. Squibb & Sons, L.L.C.$4,925Research paymentCash or cash equivalentConnect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist2025
2025-04-02Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-04-01PFIZER INC.$13,018Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-03-29Fisher Scientific Company L.L.C.$1,294Debt forgivenessCash or cash equivalent2025
2025-03-26Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-03-26Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-03-12Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-03-06Genentech, Inc.$1,709Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-03-05Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-03-03Baxter Healthcare$3,179Debt forgivenessIn-kind items and services Device, Devices2025
2025-02-24AstraZeneca Pharmaceuticals LP$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentIMFINZI Biological, Oncology2025
2025-02-05Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-29Insulet Corporation$925Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-28Genentech, Inc.$52Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-01-23Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-21Genentech, Inc.$985Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2025
2025-01-15PFIZER INC.$1,230Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-01-09E.R. Squibb & Sons, L.L.C.$122,119Research paymentCash or cash equivalentA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr2025
2025-01-09PFIZER INC.$9,229Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2025
2025-01-01Novartis Pharmaceuticals Corporation$8,050Research paymentCash or cash equivalentSCEMBLIX Drug, OncologyA Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase 2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Western Connecticut Planning RegionStamford city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
Stamford, CT
County
Western Connecticut Planning Region, CT
State
Connecticut
Population B01003137,144627,0713,624,508
Population, 2020 census P1135,470-3,605,944
Median age B0100238.441.541.1
Under 18 B0100118.4%21.8%20.2%
65 and over B0100116.2%17.4%18.5%
Households B1100155,291235,3791,434,007
Foreign born B0500231.3%23.8%15.7%
Median household income B19013$111,586$128,188$95,781
Median family income B19113$126,493$161,625$122,706
Per capita income B19301$67,068$82,266$55,915
Poverty rate B1700110.1%7.5%10.0%
Unemployment rate B230254.9%5.3%5.6%
Civilian labor force B2302581,944346,5571,959,490
Mean commute (minutes) B0801328.530.826.5
Bachelor's degree or higher B1500351.7%55.5%42.5%
Housing units B2500158,655251,5301,541,822
Owner-occupied B2500348.8%66.4%66.5%
Renters B2500351.2%33.6%33.5%
Median home value B25077$624,400$652,900$366,900
Median gross rent B25064$2,276$2,110$1,488
White, not Hispanic B0300243.2%58.6%61.9%
Black B0300217.7%9.3%9.8%
Hispanic or Latino B0300228.3%20.5%18.3%
Asian B030027.3%5.4%4.7%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.